• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

COVID-19 与结核分枝杆菌合并感染的免疫反应：系统评价

Immune responses in COVID-19 and tuberculosis coinfection: A scoping review.

机构信息

Universidad Nacional de San Agustín de Arequipa, Arequipa, Peru.

Grupo de Investigación en Inmunología - GII, UNSA, Arequipa, Peru.

出版信息

Front Immunol. 2022 Aug 26;13:992743. doi: 10.3389/fimmu.2022.992743. eCollection 2022.

DOI:10.3389/fimmu.2022.992743
PMID:36090983
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9459402/
Abstract

BACKGROUND AND AIM

Patients with COVID-19 and tuberculosis coinfection are at an increased risk of severe disease and death. We therefore sought to evaluate the current evidence which assessed the immune response in COVID-19 and tuberculosis coinfection.

METHODS

We searched Pubmed/MEDLINE, EMBASE, Scopus, and Web of Science to identify articles published between 2020 and 2021. We included observational studies evaluating the immune response in patients with tuberculosis and COVID-19 compared to patients with COVID-19 alone.

RESULTS

Four cross-sectional studies (372 participants) were identified. In patients with asymptomatic COVID-19 and latent tuberculosis (LTBI), increased cytokines, chemokines, growth factors and humoral responses were found. In addition, patients with symptomatic COVID-19 and LTBI had higher leukocytes counts and less inflammation. Regarding patients with COVID-19 and active tuberculosis (aTB), they exhibited decreased total lymphocyte counts, CD4 T cells specific against SARS-CoV-2 and responsiveness to SARS-CoV-2 antigens compared to patients with only COVID-19.

CONCLUSION

Although the evidence is limited, an apparent positive immunomodulation is observed in patients with COVID-19 and LTBI. On the other hand, patients with COVID-19 and aTB present a dysregulated immune response. Longitudinal studies are needed to confirm these findings and expand knowledge.

摘要

背景和目的

COVID-19 和结核分枝杆菌合并感染的患者发生重症和死亡的风险增加。因此，我们评估了评估 COVID-19 和结核分枝杆菌合并感染患者免疫反应的现有证据。

方法

我们检索了 Pubmed/MEDLINE、EMBASE、Scopus 和 Web of Science，以确定 2020 年至 2021 年期间发表的文章。我们纳入了评估结核分枝杆菌和 COVID-19 患者与单纯 COVID-19 患者免疫反应的观察性研究。

结果

确定了四项横断面研究（372 名参与者）。在无症状 COVID-19 和潜伏性结核（LTBI）患者中，发现细胞因子、趋化因子、生长因子和体液反应增加。此外，有症状的 COVID-19 和 LTBI 患者的白细胞计数较高，炎症较少。对于 COVID-19 和活动性结核（aTB）患者，与仅患有 COVID-19 的患者相比，他们的总淋巴细胞计数、针对 SARS-CoV-2 的 CD4 T 细胞和对 SARS-CoV-2 抗原的反应性降低。

结论

尽管证据有限，但 COVID-19 和 LTBI 患者的免疫调节似乎呈阳性。另一方面，COVID-19 和 aTB 患者的免疫反应失调。需要进行纵向研究来证实这些发现并扩展知识。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4222/9459402/a7280f0b3d85/fimmu-13-992743-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4222/9459402/82463b3d08a3/fimmu-13-992743-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4222/9459402/a7280f0b3d85/fimmu-13-992743-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4222/9459402/82463b3d08a3/fimmu-13-992743-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4222/9459402/a7280f0b3d85/fimmu-13-992743-g002.jpg

相似文献

1
Immune responses in COVID-19 and tuberculosis coinfection: A scoping review.COVID-19 与结核分枝杆菌合并感染的免疫反应：系统评价
Front Immunol. 2022 Aug 26;13:992743. doi: 10.3389/fimmu.2022.992743. eCollection 2022.
2
Latent tuberculosis co-infection is associated with heightened levels of humoral, cytokine and acute phase responses in seropositive SARS-CoV-2 infection.潜伏性结核合并感染与血清阳性 SARS-CoV-2 感染中体液、细胞因子和急性期反应水平升高有关。
J Infect. 2021 Sep;83(3):339-346. doi: 10.1016/j.jinf.2021.07.029. Epub 2021 Jul 28.
3
Coinfection of tuberculosis and COVID-19 limits the ability to in vitro respond to SARS-CoV-2.结核分枝杆菌和 COVID-19 的双重感染限制了体外对 SARS-CoV-2 的反应能力。
Int J Infect Dis. 2021 Dec;113 Suppl 1:S82-S87. doi: 10.1016/j.ijid.2021.02.090. Epub 2021 Mar 10.
4
Relationship of SARS-CoV-2-specific CD4 response to COVID-19 severity and impact of HIV-1 and tuberculosis coinfection.SARS-CoV-2 特异性 CD4 反应与 COVID-19 严重程度的关系以及 HIV-1 和结核分枝杆菌合并感染的影响。
J Clin Invest. 2021 Jun 15;131(12). doi: 10.1172/JCI149125.
5
Immune interaction between SARS-CoV-2 and .SARS-CoV-2 与. 之间的免疫相互作用。
Front Immunol. 2023 Sep 27;14:1254206. doi: 10.3389/fimmu.2023.1254206. eCollection 2023.
6
TB and COVID-19: An Exploration of the Characteristics and Resulting Complications of Co-infection.结核病和 COVID-19：合并感染的特征和相关并发症探讨。
Front Biosci (Schol Ed). 2022 Mar 1;14(1):6. doi: 10.31083/j.fbs1401006.
7
Characterization of the immune impairment of patients with tuberculosis and COVID-19 coinfection.结核和 COVID-19 共感染患者免疫损伤的特征。
Int J Infect Dis. 2023 May;130 Suppl 1:S34-S42. doi: 10.1016/j.ijid.2023.03.021. Epub 2023 Mar 21.
8
Effect of SARS-CoV-2 seropositivity on antigen - specific cytokine and chemokine responses in latent tuberculosis.新型冠状病毒血清阳性对潜伏性结核抗原特异性细胞因子和趋化因子反应的影响。
Cytokine. 2022 Feb;150:155785. doi: 10.1016/j.cyto.2021.155785. Epub 2021 Dec 14.
9
Pathogenesis of SARS-CoV-2 and Coinfection.SARS-CoV-2 的发病机制及合并感染。
Front Immunol. 2022 Jun 16;13:909011. doi: 10.3389/fimmu.2022.909011. eCollection 2022.
10
Immune Dysregulation in SARS-CoV-2 patients coinfected with Mycobacterium tuberculosis (Mtb) or HIV in China.中国 SARS-CoV-2 患者合并结核分枝杆菌（Mtb）或 HIV 感染后的免疫失调。
BMC Public Health. 2024 Feb 22;24(1):556. doi: 10.1186/s12889-024-17905-3.

引用本文的文献

1
Functional and structural insights into the multicopper oxidase MmcO from : implications for drug targeting.来自[具体来源]的多铜氧化酶MmcO的功能和结构见解：对药物靶向的启示
Front Chem. 2025 May 27;13:1565715. doi: 10.3389/fchem.2025.1565715. eCollection 2025.
2
Latent tuberculosis coinfection in mild COVID-19 is associated with a distinct immune cell phenotype marked by enhanced cytotoxic degranulation and mitochondrial alterations.轻度新冠肺炎中的潜伏性结核合并感染与一种独特的免疫细胞表型相关，其特征为细胞毒性脱颗粒增强和线粒体改变。
Front Immunol. 2025 May 19;16:1566449. doi: 10.3389/fimmu.2025.1566449. eCollection 2025.
3

本文引用的文献

1
The T-cell response to SARS-CoV-2: kinetic and quantitative aspects and the case for their protective role.T细胞对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的反应：动力学和定量方面及其保护作用的实例
Oxf Open Immunol. 2021 Feb 23;2(1):iqab006. doi: 10.1093/oxfimm/iqab006. eCollection 2021.
2
The T cell immune response against SARS-CoV-2.针对 SARS-CoV-2 的 T 细胞免疫应答。
Nat Immunol. 2022 Feb;23(2):186-193. doi: 10.1038/s41590-021-01122-w. Epub 2022 Feb 1.
3
Implications of SARS-CoV-2 infection on the clinical, hematological, and inflammatory parameters in COVID-19 patients: A retrospective cross-sectional study.
Self-reported COVID-19 severity among persons with tuberculosis infection in western Kenya, 2021.
2021年肯尼亚西部结核病感染者自我报告的新冠病毒病严重程度
PLOS Glob Public Health. 2025 Apr 30;5(4):e0004372. doi: 10.1371/journal.pgph.0004372. eCollection 2025.
4
Comparative Insights into COVID-19 and Tuberculosis: Clinical Manifestations, Inflammatory Markers, and Outcomes in Pulmonary Versus Extrapulmonary Tuberculosis and Co-Infection.对 COVID-19 与结核病的比较见解：肺结核与肺外结核及合并感染中的临床表现、炎症标志物和结局
J Clin Med. 2025 Apr 17;14(8):2782. doi: 10.3390/jcm14082782.
5
Nuances in the global impact of COVID-19 on tuberculosis control efforts: An updated review.新冠疫情对结核病防控工作全球影响的细微差别：最新综述
Medicine (Baltimore). 2025 Apr 18;104(16):e42195. doi: 10.1097/MD.0000000000042195.
6
Coinfections in Tuberculosis in Low- and Middle-Income Countries: Epidemiology, Clinical Implications, Diagnostic Challenges, and Management Strategies-A Narrative Review.低收入和中等收入国家结核病合并感染：流行病学、临床意义、诊断挑战及管理策略——一篇叙述性综述
J Clin Med. 2025 Mar 21;14(7):2154. doi: 10.3390/jcm14072154.
7
Impact of Severity of COVID-19 in TB Disease Patients: Experience from an Italian Infectious Disease Referral Hospital.2019冠状病毒病（COVID-19）严重程度对结核病患者的影响：来自一家意大利传染病转诊医院的经验
Infect Dis Rep. 2025 Feb 5;17(1):11. doi: 10.3390/idr17010011.
8
The effect of previous SARS-CoV-2 infection on systemic immune responses in individuals with tuberculosis.既往 SARS-CoV-2 感染对结核患者全身免疫反应的影响。
Front Immunol. 2024 Jun 27;15:1357360. doi: 10.3389/fimmu.2024.1357360. eCollection 2024.
9
Spatio-Temporal Pattern of Tuberculosis Distribution in Romania and Particulate Matter Pollution Associated With Risk of Infection.罗马尼亚结核病分布的时空模式以及与感染风险相关的颗粒物污染
Geohealth. 2024 Feb 6;8(2):e2023GH000972. doi: 10.1029/2023GH000972. eCollection 2024 Feb.
10
Impact of Tuberculosis on Disease Severity and Viral Shedding Duration in COVID-19 Patients.结核病对 COVID-19 患者疾病严重程度和病毒脱落持续时间的影响。
Viruses. 2024 Feb 6;16(2):260. doi: 10.3390/v16020260.
严重急性呼吸综合征冠状病毒 2 感染对 COVID-19 患者临床、血液学和炎症参数的影响：一项回顾性横断面研究。
J Infect Public Health. 2022 Feb;15(2):214-221. doi: 10.1016/j.jiph.2021.12.013. Epub 2022 Jan 6.
4
Impact of Latent Tuberculosis on Severity and Outcomes in Admitted COVID-19 Patients.潜伏性结核对新冠病毒肺炎住院患者病情严重程度及预后的影响
Cureus. 2021 Nov 25;13(11):e19882. doi: 10.7759/cureus.19882. eCollection 2021 Nov.
5
Effect of BCG Revaccination on Occupationally Exposed Medical Personnel Vaccinated against SARS-CoV-2.BCG 复种对 SARS-CoV-2 疫苗接种的职业暴露医务人员的影响。
Cells. 2021 Nov 15;10(11):3179. doi: 10.3390/cells10113179.
6
Active pulmonary tuberculosis and coronavirus disease 2019: A systematic review and meta-analysis.活动性肺结核与 2019 冠状病毒病：系统评价和荟萃分析。
PLoS One. 2021 Oct 21;16(10):e0259006. doi: 10.1371/journal.pone.0259006. eCollection 2021.
7
Risk assessment of latent tuberculosis infection through a multiplexed cytokine biosensor assay and machine learning feature selection.基于多重细胞因子生物传感器检测和机器学习特征选择的潜伏性结核感染风险评估。
Sci Rep. 2021 Oct 15;11(1):20544. doi: 10.1038/s41598-021-99754-3.
8
COVID-19 and Tuberculosis Coinfection: An Overview of Case Reports/Case Series and Meta-Analysis.2019冠状病毒病与结核病合并感染：病例报告/病例系列及荟萃分析概述
Front Med (Lausanne). 2021 Aug 24;8:657006. doi: 10.3389/fmed.2021.657006. eCollection 2021.
9
Th2/Th1 Cytokine Imbalance Is Associated With Higher COVID-19 Risk Mortality.Th2/Th1细胞因子失衡与新冠病毒感染高死亡风险相关。
Front Genet. 2021 Jul 16;12:706902. doi: 10.3389/fgene.2021.706902. eCollection 2021.
10
Latent tuberculosis co-infection is associated with heightened levels of humoral, cytokine and acute phase responses in seropositive SARS-CoV-2 infection.潜伏性结核合并感染与血清阳性 SARS-CoV-2 感染中体液、细胞因子和急性期反应水平升高有关。
J Infect. 2021 Sep;83(3):339-346. doi: 10.1016/j.jinf.2021.07.029. Epub 2021 Jul 28.